KD Logo

Taysha Gene Therapies Inc [TSHA] Investment Guide: What You Need to Know

Taysha Gene Therapies Inc’s recent filing unveils that its 10% Owner Manning Paul B acquired Company’s shares for reported $3.0 million on Jun 27 ’24. In the deal valued at $2.25 per share,1,333,333 shares were bought. As a result of this transaction, Manning Paul B now holds 1,333,333 shares worth roughly $2.96 million.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Then, Manning Paul B bought 100,000 shares, generating $163,000 in total proceeds. Upon buying the shares at $1.63, the 10% Owner now owns 16,566,667 shares.

Before that, Alam Kamran sold 33,000 shares. Taysha Gene Therapies Inc shares valued at $76,890 were divested by the Chief Financial Officer at a price of $2.33 per share. As a result of the transaction, Alam Kamran now holds 258,042 shares, worth roughly $0.57 million.

BMO Capital Markets initiated its Taysha Gene Therapies Inc [TSHA] rating to an Outperform in a research note published on June 27, 2024; the price target was $5. A number of analysts have revised their coverage, including Piper Sandler’s analysts, who began to cover the stock in early April with a ‘”an Overweight”‘ rating. Jefferies also remained covering TSHA and has decreased its forecast on February 01, 2023 with a “Hold” recommendation from previously “Buy” rating. Morgan Stanley revised its rating on January 27, 2023. It rated TSHA as “an Equal-weight” which previously was an “an Overweight”.

Price Performance Review of TSHA

On Monday, Taysha Gene Therapies Inc [NASDAQ:TSHA] saw its stock jump 7.25% to $2.22. Over the last five days, the stock has lost -0.89%. Taysha Gene Therapies Inc shares have risen nearly 25.42% since the year began. Nevertheless, the stocks have risen 232.39% over the past one year. While a 52-week high of $4.32 was reached on 06/13/24, a 52-week low of $0.62 was recorded on 01/19/24. SMA at 50 days reached $2.92, while 200 days put it at $2.35. A total of 1.51 million shares were traded, compared to the trading of 0.81 million shares in the previous session.

Levels Of Support And Resistance For TSHA Stock

The 24-hour chart illustrates a support level at 2.12, which if violated will result in even more drops to 2.01. On the upside, there is a resistance level at 2.29. A further resistance level may holdings at 2.36. The Relative Strength Index (RSI) on the 14-day chart is 37.58, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.36, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 82.59%. Stochastics%K at 13.51% indicates the stock is a buying.

Most Popular